Abstract
In systemic autoimmune rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), the interaction between hyperactive T cells and B cells causes a dysregulated production of autoantibodies that can lead to tissue damage, with subsequent impaired organ function and disability. The available information on the immune cells that participate in this process has led to the development of several approaches that can influence disease course. One of these approaches uses immunomodulatory peptides that mimic selected sequences involved in the interaction between T and B cells. Preclinical studies in animal models have given encouraging results, and synthetic peptidebased intervention in human autoimmune rheumatic diseases is now approaching translational work into clinical settings.
Keywords: Systemic autoimmunity, synthetic peptides, immune modulation
Current Clinical Pharmacology
Title: Mimicking Self-Antigens with Synthetic Peptides in Systemic Autoimmune Rheumatic Diseases
Volume: 4 Issue: 2
Author(s): Chunlin Cai and Antonio La Cava
Affiliation:
Keywords: Systemic autoimmunity, synthetic peptides, immune modulation
Abstract: In systemic autoimmune rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), the interaction between hyperactive T cells and B cells causes a dysregulated production of autoantibodies that can lead to tissue damage, with subsequent impaired organ function and disability. The available information on the immune cells that participate in this process has led to the development of several approaches that can influence disease course. One of these approaches uses immunomodulatory peptides that mimic selected sequences involved in the interaction between T and B cells. Preclinical studies in animal models have given encouraging results, and synthetic peptidebased intervention in human autoimmune rheumatic diseases is now approaching translational work into clinical settings.
Export Options
About this article
Cite this article as:
Cai Chunlin and Cava La Antonio, Mimicking Self-Antigens with Synthetic Peptides in Systemic Autoimmune Rheumatic Diseases, Current Clinical Pharmacology 2009; 4 (2) . https://dx.doi.org/10.2174/157488409788184936
DOI https://dx.doi.org/10.2174/157488409788184936 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets A Systematic Review And Meta-Analysis of Clinical Trials of Mesenchymal Stem Cell Therapy for Cartilage Repair
Current Stem Cell Research & Therapy PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution
Current Drug Metabolism Phosphodiesterase 7A: A New Therapeutic Target for Alleviating Chronic Inflammation?
Current Pharmaceutical Design ω-3 Polyunsaturated Fatty Acids Effects on the Cardiometabolic Syndrome and their Role in Cardiovascular Disease Prevention: An Update from the Recent Literature
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Molecular Study of FMF Patients in Armenia
Current Drug Targets - Inflammation & Allergy Formulation and Characterizations of Delayed Release Multi-Particulates System of Indomethacin: Optimization by Response Surface Methodology
Current Drug Delivery Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab
Current Drug Safety VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation, Serotonin and Major Depression
Current Drug Targets Management and Treatment of Dengue and Chikungunya - Natural Products to the Rescue
Combinatorial Chemistry & High Throughput Screening Ectopic Lymphoid Neogenesis and Lymphoid Chemokines in Sjogren’s Syndrome: At the Interplay between Chronic Inflammation, Autoimmunity and Lymphomagenesis
Current Pharmaceutical Biotechnology The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry S100A8/A9 as a Pro-inflammatory Cytokine in Obstructive Airway Disease Via the Multi-Ligand Receptor, RAGE
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies The ERK and p38MAPK Pathways as Targets for Anti-Inflammatory Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Multivalent & Multifunctional Ligands to β-Amyloid
Current Pharmaceutical Design Enlarging the NSAIDs Family: Ether, Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Novel Anti-Inflammatory and Analgesic Agents
Current Medicinal Chemistry